AMGN AMGEN Inc.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Company profile
Ticker
AMGN
Exchange
Website
CEO
Robert A. Bradway
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
AMGEN
SEC CIK
Corporate docs
IRS number
953540776
AMGN stock data
()
Calendar
29 Oct 20
3 Dec 20
31 Dec 20
News
Financial summary
| Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from AMGEN earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 9 Nov 20 | Williams R Sanders | Common Stock | Sell | Dispose S | Yes | 242.4 | 250 | 60.6K | 4,909 |
| 2 Nov 20 | Kullman Ellen Jamison | Common Stock | Grant | Aquire A | No | 0 | 140.775 | 0 | 6,846.072 |
| 2 Nov 20 | Gordon Murdo | Common Stock | Payment of exercise | Dispose F | No | 216.94 | 6,269 | 1.36M | 32,036 |
| 2 Nov 20 | Linda H. Louie | Common Stock | Grant | Aquire A | No | 0 | 1,453 | 0 | 7,632 |
| 2 Nov 20 | David M Reese | Common Stock | Payment of exercise | Dispose F | No | 216.94 | 2,125 | 461K | 39,619 |
Institutional ownership Q3 2020
75.2% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 2053 |
| Opened positions | 140 |
| Closed positions | 122 |
| Increased positions | 818 |
| Reduced positions | 761 |
13F shares |
Current |
|---|---|
| Total value | 111.96B |
| Total shares | 437.76M |
| Total puts | 3.67M |
| Total calls | 4.12M |
| Total put/call ratio | 0.9 |
Largest owners |
Shares | Value |
|---|---|---|
| BLK Blackrock | 47.99M | $12.2B |
| Vanguard | 47.94M | $12.18B |
| Capital Research Global Investors | 33.5M | $8.51B |
| STT State Street | 31.28M | $7.95B |
| Primecap Management | 17.41M | $4.42B |
| FMR | 14.2M | $3.61B |
| Geode Capital Management | 9.17M | $2.33B |
| MS Morgan Stanley | 8.57M | $2.18B |
| JPM JPMorgan Chase & Co. | 8.27M | $2.05B |
| NTRS Northern Trust | 8.14M | $2.07B |
Financial report summary
?Competition
Scios • Poniard Pharmaceuticals • Imclone Systems • Ir Biosciences • Celgene • ImmunoCellular Therapeutics • Novelion Therapeutics • Spectrum Pharmaceuticals • Medimmune • GenaeraManagement Discussion
- Future sales of our products will depend in part on the factors discussed in the Overview, Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition, in Part I, Item 1A. Risk Factors, and any additional factors discussed in the individual product sections below. In addition, for a list of our products’ significant competitors, see Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition.
- The increase in ENBREL sales for 2019 was driven primarily by favorable impacts from changes in accounting estimates of sales deductions and an increase in net selling price, offset partially by lower unit demand. For 2020, we expect the trend of lower unit demand to continue.
- The decrease in ENBREL sales for 2018 was driven primarily by lower unit demand and net selling price.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
accreted, aforementioned, aggressive, altered, attack, audit, bear, Blaylock, BNP, BofA, boosting, buildup, cardiovascular, cell, certiorari, compounded, cutoff, dealer, death, Deutsche, dispute, DKd, docetaxel, ecosystem, enduring, England, expansion, featured, hazard, HHS, interpretation, intervene, Journal, laboratory, lose, Mankind, median, MM, Morgan, mutation, newly, NSCLC, opposed, ORR, owed, predominantly, promising, published, ransomware, RBC, recommenced, recruiting, recruitment, recurrent, regimen, repeal, Run, secondary, Servier, Shank, Siebert, Slate, solid, system, text, thereof, titled, topline, underemployment, underway, uninsured, validly, Van, weekly, writ
Removed:
aggregated, benchmark, Cipla, complaint, convertase, covered, denial, draft, France, Genentech, Germany, Graham, granted, Hope, infringed, involvement, Island, Japan, Jonathan, Kabi, Kingdom, noninfringement, patentability, proprotein, pursuing, Rhode, stipulation, swissbiosim, upholding, valid
Financial reports
10-Q
2020 Q3
Quarterly report
29 Oct 20
10-Q
2020 Q2
Quarterly report
29 Jul 20
10-Q
2020 Q1
Quarterly report
1 May 20
10-K/A
2019 FY
Annual report (amended)
13 Feb 20
10-K
2019 FY
Annual report
12 Feb 20
10-Q
2019 Q3
Quarterly report
30 Oct 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
1 May 19
10-K
2018 FY
Annual report
13 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
Current reports
8-K
Amgen Reports Third Quarter 2020 Financial Results
28 Oct 20
8-K
Entry into a Material Definitive Agreement
18 Aug 20
8-K
Amgen Announces Early Tender Results
14 Aug 20
8-K
Other Events
30 Jul 20
8-K
Amgen Reports Second Quarter 2020 Financial Results
28 Jul 20
8-K
Departure of Directors or Certain Officers
23 Jul 20
8-K
Departure of Directors or Certain Officers
23 Jul 20
8-K
Submission of Matters to a Vote of Security Holders
20 May 20
8-K
Entry into a Material Definitive Agreement
6 May 20
8-K
Amgen Reports First Quarter 2020 Financial Results
30 Apr 20
Registration and prospectus
424B2
Prospectus for primary offering
6 May 20
FWP
Free writing prospectus
5 May 20
424B3
Prospectus supplement
4 May 20
424B2
Prospectus for primary offering
20 Feb 20
FWP
Free writing prospectus
18 Feb 20
424B3
Prospectus supplement
18 Feb 20
S-3ASR
Automatic shelf registration
10 Feb 20
SC TO-I/A
Issuer tender offer statement (amended)
8 Mar 18
SC TO-I/A
Issuer tender offer statement (amended)
6 Mar 18
SC TO-I/A
Issuer tender offer statement (amended)
26 Feb 18
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
PX14A6G
Letter to shareholders
15 Apr 20
DEFA14A
Additional proxy soliciting materials
13 Apr 20
DEFA14A
Additional proxy soliciting materials
7 Apr 20
DEF 14A
Definitive proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
13 May 19
DEFA14A
Additional proxy soliciting materials
2 May 19
DEFA14A
Additional proxy soliciting materials
29 Apr 19
DEFA14A
Additional proxy soliciting materials
22 Apr 19
Other
CT ORDER
Confidential treatment order
24 Oct 19
CT ORDER
Confidential treatment order
3 Jun 19
CT ORDER
Confidential treatment order
30 May 18
CT ORDER
Confidential treatment order
17 May 18
CT ORDER
Confidential treatment order
4 Dec 17
CT ORDER
Confidential treatment order
8 Sep 17
CT ORDER
Confidential treatment order
15 Aug 17
CT ORDER
Confidential treatment order
26 May 17
CT ORDER
Confidential treatment order
8 May 17
CT ORDER
Confidential treatment order
6 Mar 17
Ownership
4
AMGEN / R Sanders Williams ownership change
10 Nov 20
4
AMGEN / DAVID M REESE ownership change
5 Nov 20
4
AMGEN / Linda H. Louie ownership change
5 Nov 20
4
AMGEN / Murdo Gordon ownership change
5 Nov 20
4
AMGEN / Ellen Jamison Kullman ownership change
4 Nov 20
4
Change in insider ownership
25 Aug 20
4
Change in insider ownership
24 Aug 20
4
Change in insider ownership
20 Aug 20
4
AMGEN / RONALD D SUGAR ownership change
19 Aug 20
4
AMGEN / R Sanders Williams ownership change
10 Aug 20
Patents
GRANT
Utility
Injector and method of assembly
1 Dec 20
An injector may include a container having a wall with an interior surface defining a closed sterile reservoir filled with a drug product.
GRANT
Utility
Interleukin-2 muteins for the expansion of T-regulatory cells
1 Dec 20
Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production.
GRANT
Utility
Antibody constructs for CD70 and CD3
1 Dec 20
The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell.
APP
Utility
Solid State Forms
26 Nov 20
The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
APP
Utility
Methods for the Treatment of Diseases Ameliorated by PDE4 Inhibition Using Dosage Titration of Apremilast
26 Nov 20
Methods of treating, managing or preventing diseases ameliorated by inhibiting PDE4 such as psoriasis, ankylosing spondylitis, Behcet's disease, rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis are disclosed.